HealthcareServices

Cardiac Amyloidosis Market Anticipated to Record Steady Gains, Advancing to $8.7 Billion by 2030

February 20, 2026February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the cardiac amyloidosis market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Cardiac Amyloidosis Market between 2026 and 2030?

The cardiac amyloidosis market has demonstrated significant expansion in recent years. It is anticipated to increase from $5.73 billion in 2025 to $6.24 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. The historical growth can be attributed to several factors, including enhanced recognition of rare cardiac disorders, progress in echocardiography and MRI diagnostic techniques, an increase in reported amyloidosis cases, the expansion of specialist cardiology clinics, and the growing availability of supportive care options.

The cardiac amyloidosis market is anticipated to experience robust expansion in the coming years, with projections indicating a growth to $8.71 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.7%. This growth over the forecast period is primarily driven by the increasing development of disease-modifying therapies, the rising adoption of genetic testing, the expansion of specialized amyloidosis treatment centers, growing investment in rare disease research, and an increasing focus on personalized cardiac therapies. Significant trends expected during this period include a heightened emphasis on early and accurate diagnosis, the rising adoption of advanced cardiac imaging techniques, the growing use of biomarker-based screening, the expansion of targeted therapeutic approaches, and enhanced awareness among cardiologists.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21128&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Cardiac Amyloidosis Market?

The expanding elderly population is projected to fuel the growth of the cardiac amyloidosis market moving forward. The geriatric population refers to individuals aged 65 and above who may require specialized medical attention and support due to age-related changes. This demographic is increasing as a result of rising life expectancy, advancements in healthcare, and declining birth rates. The growing geriatric population leads to an elevated prevalence of cardiac amyloidosis, as aging stands as a significant risk factor for the accumulation of amyloid protein within the heart. For instance, in January 2024, the Population Reference Bureau, a US-based nonprofit organization, reported that the US population aged 65 and older is anticipated to increase from 58 million in 2022 to 82 million by 2050, marking a 47% surge. Therefore, the increasing geriatric population will stimulate the cardiac amyloidosis market.

What Segments Are Included Within The Cardiac Amyloidosis Market?

The cardiac amyloidosis market covered in this report is segmented –

1) By Product Type: Light Chain Amyloidosis, Transthyretin Amyloidosis

2) By Treatment: Chemotherapy, Supportive Care, Stem Cell Transplant, Targeted Therapy

3) By End-User: Hospitals, Clinics

Subsegments:

1) By Light Chain Amyloidosis: AL (Immunoglobulin Light Chain) Amyloidosis with Cardiac Involvement, AL Amyloidosis without Cardiac Involvement

2) By Transthyretin Amyloidosis: Hereditary Transthyretin Amyloidosis (ATTRm), Wild-type Transthyretin Amyloidosis (ATTRwt)

Which Trends Are Influencing The Performance And Direction Of The Cardiac Amyloidosis Market?

Major companies operating in the cardiac amyloidosis market are prioritizing technological advancements, such as artificial intelligence (AI)-based software-only diagnostic instruments, to improve early detection and enhance clinical outcomes for individuals with this frequently underdiagnosed disease. An artificial intelligence (AI)-powered, software-exclusive medical device capable of detecting cardiac amyloidosis serves as a diagnostic tool that employs artificial intelligence to analyze echocardiographic images and identify indicators of the illness without necessitating additional hardware or extensive clinical data. For instance, in November 2024, Ultromics Ltd., a UK-based health technology company, secured FDA clearance for EchoGo Amyloidosis, an AI-driven clinical tool designed for the early detection of cardiac amyloidosis. This product is the first device within the FDA’s Total Product Lifecycle Advisory Program (TAP) to receive marketing authorization. By utilizing artificial intelligence, EchoGo Amyloidosis analyzes echocardiograms to detect the disease from a single clip, thereby addressing the critical need for an earlier diagnosis before its unnoticed progression.

Who Are The Prominent Global Companies Shaping The Cardiac Amyloidosis Market Landscape?

Major companies operating in the cardiac amyloidosis market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Prothena Corp, Intellia Therapeutics Inc., Neurimmune AG, Attralus Inc., Oncopeptides, SOM Biotech, Amylyx Pharmaceuticals, AstraZeneca plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bristol Myers Squibb Company, AbbVie Inc., Roche Holding AG, Johnson & Johnson, CSL Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/cardiac-amyloidosis-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Cardiac Amyloidosis Market?

North America was the largest region in the cardiac amyloidosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Cardiac Amyloidosis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21128&type=smp

Browse Through More Reports Similar to the Global Cardiac Amyloidosis Market 2026, By The Business Research Company

Ventricular Fibrillation Market Report 2026

https://www.thebusinessresearchcompany.com/report/ventricular-fibrillation-global-market-report

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Cardiac Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiac-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795